125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)
- Resource Type
- Abstract
- Source
- In
Immuno-Oncology and Technology December 2022 16 Supplement 1 - Subject
- Language
- ISSN
- 2590-0188